Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,602.00GBp
2:39pm IST
Change (% chg)

-7.00 (-0.12%)
Prev Close
5,609.00
Open
5,613.00
Day's High
5,642.00
Day's Low
5,593.00
Volume
180,862
Avg. Vol
1,944,741
52-wk High
5,665.37
52-wk Low
4,260.00

Select another date:

Wed, Jul 18 2018

Photo

AstraZeneca to stockpile drugs as Brexit 'safety net'

LONDON AstraZeneca is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal.

AstraZeneca to stockpile drugs as Brexit 'safety net'

LONDON AstraZeneca is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal.

AstraZeneca to stockpile drugs as Brexit 'safety net'

LONDON, July 18 AstraZeneca is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal.

Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

LONDON AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

Hitting cancer early: AstraZeneca's bid to outmanoeuvre rivals

LONDON AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

FOCUS-Hitting cancer early: AstraZeneca's bid to outmanoeuvre rivals

* Drugmaker gets its mojo back a year after cancer study flop

AstraZeneca, Merck eye $1 billion boost from cancer drug success

LONDON AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

UPDATE 1-AstraZeneca, Merck eye $1 bln boost from cancer drug success

* Puts drug ahead of competition in PARP medicine race (Adds analyst reaction, sales forecasts)

AstraZeneca, Merck eye wider cancer drug use after study success

LONDON, June 27 AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

Select another date: